Oncodesign and Servier Hit First Milestone in Developing LRRK2 Inhibitors for Parkinson’s

Oncodesign and Servier Hit First Milestone in Developing LRRK2 Inhibitors for Parkinson’s
Oncodesign and Servier have reached the first key milestone months ahead of schedule in their partnership to develop LRRK2 inhibitors for Parkinson’s disease, the companies announced in a press release. “The collaboration works perfectly and both teams are up to the challenges,” said Philippe Genne, PhD, Oncodesign’s founder and CEO. “The results were obtained sooner than expected which allowed us ... read more
Source: Parkinson’s News TodayPublished on 2020-02-19By Marisa Wexler